A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

Study Summary

The main objectives of this study are to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies, and to evaluate the efficacy of bemarituzumab in combination with S-1 and oxaliplatin (SOX) and nivolumab as assessed by objective response.

Conditions

Gastric Cancer Gastroesophageal Junction Cancer

Interventions / Drugs

Bemarituzumab CAPOX SOX Nivolumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment72 participants

Primary Completion—

Lead SponsorAmgen

Data Retrieved2026-04-13 18:29:34.157849+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.